Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group.

Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799.

PMID:
21685536
2.

[Resistance to darunavir].

García Deltoro M.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:51-60. Review. Spanish.

PMID:
19195460
3.
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
6.

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Mauskopf J, Annemans L, Hill AM, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:1-16. doi: 10.2165/11587410-000000000-00000. Review.

PMID:
21182340
7.

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Lefebvre E, Schiffer CA.

AIDS Rev. 2008 Jul-Sep;10(3):131-42. Review.

8.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

Ripamonti D, Hill A, Lauthouwers E, van Delft Y, Moecklinghoff C.

AIDS Rev. 2013 Oct-Dec;15(4):230-6. Review.

PMID:
24322383
9.

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.

McKeage K, Scott LJ.

Paediatr Drugs. 2010 Apr 1;12(2):123-31. doi: 10.2165/11204530-000000000-00000. Review.

PMID:
20218748
10.

Darunavir (TMC114): a new HIV-1 protease inhibitor.

Molina JM, Hill A.

Expert Opin Pharmacother. 2007 Aug;8(12):1951-64. Review.

PMID:
17696796
11.

Darunavir: in the treatment of HIV-1 infection.

Fenton C, Perry CM.

Drugs. 2007;67(18):2791-801. Review.

PMID:
18062724
12.

Darunavir: a second-generation protease inhibitor.

Busse KH, Penzak SR.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1593-602. Review.

PMID:
17646561
13.

Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy.

Pérez Valero I, González-Baeza A, Montes Ramírez ML.

AIDS Rev. 2014 Apr-Jun;16(2):101-8. Review.

PMID:
24937204
14.

Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".

Picchio G, De Meyer S, de Béthune MP.

AIDS. 2008 Jan 2;22(1):165-7. Review. No abstract available.

PMID:
18090413
15.

Pharmacoeconomics of darunavir.

Fullerton DS, Smets E, De La Rosa G, Mrus JM.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):27-39. doi: 10.1586/erp.10.88. Review.

PMID:
21351854
16.

Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.

Soriano V, de Mendoza C.

HIV Clin Trials. 2002 May-Jun;3(3):249-57. Review.

PMID:
12032884
17.

New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.

Rotty J, Hoy J.

Sex Health. 2008 Sep;5(3):235-41. Review.

PMID:
18771638
18.

Darunavir.

El-Atrouni WI, Temesgen Z.

Drugs Today (Barc). 2007 Oct;43(10):671-9. Review.

PMID:
17987220
19.

Darunavir: a critical review of its properties, use and drug interactions.

Ruela Corrêa JC, D'Arcy DM, dos Reis Serra CH, Nunes Salgado HR.

Pharmacology. 2012;90(1-2):102-9. doi: 10.1159/000339862. Epub 2012 Jul 12. Review.

20.

The HIVdb system for HIV-1 genotypic resistance interpretation.

Tang MW, Liu TF, Shafer RW.

Intervirology. 2012;55(2):98-101. doi: 10.1159/000331998. Epub 2012 Jan 24. Review.

PMID:
22286876
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk